A5027546968- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Virus-based gene therapy research
- Multiple Myeloma Research and Treatments
- Cytomegalovirus and herpesvirus research
- Retinoids in leukemia and cellular processes
- Immunotherapy and Immune Responses
- HIV/AIDS drug development and treatment
- Mesenchymal stem cell research
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Childhood Cancer Survivors' Quality of Life
- Pneumocystis jirovecii pneumonia detection and treatment
- Blood groups and transfusion
- Neurological Complications and Syndromes
- Neutropenia and Cancer Infections
- Complement system in diseases
- Advancements in Semiconductor Devices and Circuit Design
Soochow University
2016-2025
First Affiliated Hospital of Soochow University
2016-2025
National Clinical Research Center for Digestive Diseases
2023-2024
Jiangsu University
2024
National Clinical Research
2021-2024
Suzhou Research Institute
2007-2019
Hôpital Nord
2019
Guangzhou Blood Center
2018
Beckman Research Institute
2015
City of Hope
2015
Abstract CD19 chimeric antigen receptor (CAR) T-cell therapy has shown great success against B-cell acute lymphoblastic leukemia (B-ALL). Tandem and sequential CD19/CD22 dual-target CAR therapies have been developed to reduce the possibility of CD19-negative relapse; however, superior strategy is still uncertain. This study screened 219 patients with relapsed/refractory B-ALL who were enrolled in clinical trials either (NCT03919240) or (NCT03614858). The complete remission (CR) rates single...
Extramedullary relapse (EMR) of acute leukemia (AL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a contributor to post-transplantation mortality and remains poorly understood, especially the different characteristics EMR in patients with myelogenous (AML) those lymphoblastic (ALL). To investigate incidence, risk factors, clinical outcomes for AML ALL, we performed retrospective analysis 362 AL who underwent allo-HSCT at First affiliated Hospital Soochow University...
Abstract The tumor burden (TB) is significantly related to the severity of cytokine release syndrome (CRS) caused by CAR-T cells, but its correlation with therapeutic efficacy has not been systematically studied. This study focused on effects TB level both safety and ssCART-19 as a treatment for r/r B-ALL. Taking 5% boundary, participants were divided into 2 groups, high low groups. Under this grouping strategy, impacts differential B-ALL TBs clinical (CR rate long-term survival) profiles...
Elderly patients with acute myeloid leukemia or myelodysplastic syndromes (AML/MDS) have historically had poor prognoses. However, there has been a recent increase in the use of allogenic hematopoietic stem cell transplantation (allo-HSCT) are this patient population. Nevertheless, optimal choice donor type for remains an unmet need. Limited data exist on allo-HSCT elderly AML/MDS from China. To better understand and optimize selection patients, particularly those refractory relapsed...
Not available.
Abstract Purpose: To assess the efficacy and safety of an induction regimen composed idarubicin, cytarabine, cladribine (IAC) in patients with de novo acute myeloid leukemia (AML). Patients Methods: Adult newly diagnosed AML were randomized to IAC group (cladribine 5 mg/m2/day for days, idarubicin 8 3 cytarabine 100 7 days) IA (idarubicin 12 days at a 1:2 ratio. The primary endpoint was complete remission (CR) after induction. Secondary endpoints included 2-year overall survival (OS),...
To investigate the efficacy of chemo-free regimen in treatment patients with treatment-naive Philadelphia chromosome positive mixed phenotype acute leukemia(Ph+MPAL). The clinical data newly treated Ph+MPAL who received venetoclax (VEN), azacytidine (AZA) and tyrosine kinase inhibitors (TKIs) First Affiliated Hospital Soochow University from July 1, 2021 to October 31, 2023 were retrospectively included. last follow-up date was December 2024. complete remission/complete remission incomplete...
The current study reports the case of a 15-year-old male who presented to First Affiliated Hospital Soochow University (Suzhou, Jiangsu, China) with 3‑day history anergy and epistaxis. patient was diagnosed T‑cell acute lymphoblastic leukemia according results bone marrow examination received chemotherapy. During agranulocytosis period, developed pneumonia right upper lung (RUL). Once complete remission achieved, underwent lobectomy RUL, together amphotericin B therapy, following...
Mixed phenotype acute leukemia (MPAL) is a subtype of in which lymphoid and myeloid markers are co-expressed. Knowledge regarding the genetic features MPAL lacking due to its rarity heterogeneity. Here, we applied an integrated genomic transcriptomic approach explore molecular characteristics 176 adult patients with MPAL, including 86 T-lymphoid/myeloid (T/My MPAL-NOS), 42 Ph+ 36 B-lymphoid/myeloid (B/My 4 t(v;11q23), 8 NOS, rare types. Genetically, T/My MPAL-NOS was similar B/T but differed...
Fms-like tyrosine kinase 3 (FLT3) is frequently mutated in haematological malignancies. Although canonical FLT3 mutations including internal tandem duplications (ITDs) and domains (TKDs) have been extensively studied, little known about the clinical significance of non-canonical mutations. Here, we first profiled spectrum 869 consecutively newly diagnosed acute myeloid leukaemia (AML), myelodysplastic syndrome lymphoblastic patients. Our results showed four types depending on affected...